Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,228	$ 21,666
Accounts and other receivables		5,000
Prepaid insurance	1,169	1,136
Prepaid and other current assets	535	404
Total current assets	5,132	28,206
Other assets, noncurrent	168	168
Right-of-use assets		66
Property and equipment, net		4
Total assets	9,964	28,444
Current liabilities:
Accounts payable	158	194
Accrued compensation	708	2,582
Other accrued liabilities	917	1,452
Dividends payable		7,558
CVR derivative liability		5,000
Operating lease liability		38
Total current liabilities	1,783	16,824
CVR derivative liability, noncurrent	4,664
Total liabilities	6,447	16,824
Commitments and Contingencies (Note 8)
Stockholders’ deficit:
Convertible preferred stock, $0.001 par value, 123,418 shares authorized; 12,340 and 0 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	33,309
Common stock, $0.001 par value, 100,000,000 shares authorized, 37,978,142 and 37,756,574 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	37	37
Additional paid-in capital	384,895	389,210
Accumulated deficit	(414,724)	(410,936)
Total stockholders' equity (deficit)	3,517	(21,689)
Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)	9,964	28,444
Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable convertible preferred stock, $0.001 par value, 123,418 shares authorized; 0 and 12,340 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively		$ 33,309
GC Biopharma Corp
Current assets:
Long-term receivable from GCBP	4,664
GNI
Current assets:
Other receivables from GNI	$ 1,200